8-K: bioAffinity Technologies Reports Record Monthly Test Volume
Current Report (Form 8-K) / Press Release
bioAffinity Technologies announced a record number of CyPath Lung tests performed in October 2026, marking the highest monthly testing volume for its noninvasive lung cancer test.
Summary
- bioAffinity Technologies reported a record high for its noninvasive CyPath Lung test in October 2026, with 235 tests performed.
- This volume represents a 29% increase compared to October 2025 and is equivalent to approximately 45% of the total tests performed in the third quarter of 2026.
- The company attributes this growth to expanded commercial reach, increased physician adoption, and strengthened customer relationships.
- Additional steps to drive growth include expanding the sales team, working with patient advocacy organizations, and advancing R&D for asthma and COPD applications.
- CyPath Lung analyzes sputum using flow cytometry and AI to assess lung cancer likelihood, complementing existing diagnostic methods.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive development, indicating strong operational progress and increasing market adoption of the company's core product.
Positives
- Record monthly testing volume for CyPath Lung in October 2026, with 235 tests performed.
- A 29% increase in testing volume compared to October 2025.
- October 2026 testing volume reached approximately 45% of the total tests performed in Q3 2026.
- Demonstrated growth in test utilization by both established and new physicians.
- Expansion of the sales team to further commercialize CyPath Lung.
- Active engagement with patient advocacy organizations to strengthen community connections.
- Significant advances in R&D to apply proprietary technology to asthma and COPD.
Negatives
- The filing does not explicitly state any negative financial or operational results.
- Forward-looking statements acknowledge risks related to sustaining physician demand, reimbursement coverage, payment rates, collection delays, and establishing distribution relationships.
Risks
- Variability in monthly testing volume.
- Reimbursement coverage, payment rates, denials, and collection delays.
- The ability to establish and maintain distribution relationships and obtain government healthcare business.
- The possibility that research will not establish the clinical performance or utility needed for new applications or lead to commercially viable products.
- Historical testing volume does not establish future growth, revenue, or profitability.
Future Outlook
The company is focused on increasing awareness and utilization of CyPath Lung, building on its growing base of ordering physicians and repeat testing activity. Efforts include expanding the sales team, working with patient advocacy organizations, and advancing R&D for new applications in asthma and COPD. Forward-looking statements indicate potential challenges in sustaining demand, securing reimbursement, and developing new products.
Management Comments
- "Octobers testing volume reflects our efforts to expand the commercial reach of CyPath Lung."
- "In addition to expanding physician adoption and strengthening relationships with existing customers, we are taking additional steps to expand the reach of CyPath Lung and set the stage for long-term growth."
- "We have expanded our sales team."
- "We are working with patient advocacy organizations to strengthen our connections within the lung cancer community, and we are seeing significant advances in our R&D to apply our proprietary technology platform to asthma and COPD."
Industry Context
StockSavvy.ai notes that the increasing adoption of noninvasive diagnostic tests like CyPath Lung aligns with a broader industry trend towards earlier disease detection and less invasive patient care. The company's focus on AI and advanced analytics in diagnostics is also a key area of innovation within the biotechnology sector.
Stakeholder Impact
- Shareholders: Potential for increased revenue and market share driven by higher test utilization.
- Physicians: Access to a noninvasive test that provides additional information for lung cancer assessment, potentially improving patient management.
- Patients: Benefit from earlier and less invasive detection of lung cancer, leading to better treatment outcomes.
- Healthcare Systems: Potential for cost savings through earlier diagnosis and avoidance of unnecessary invasive procedures.
Next Steps
- Continue to expand the commercial reach of CyPath Lung.
- Expand physician adoption and strengthen relationships with existing customers.
- Expand the sales team.
- Work with patient advocacy organizations.
- Advance R&D to apply proprietary technology platform to asthma and COPD.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Year ended December 31, 2025 (referenced for SEC filings) |
| 2026-10-01 | Start of October 2026, when record testing volume was achieved. |
| 2026-10-31 | End of October 2026, when record testing volume was achieved. |
| 2026-11-11 | Date of the press release announcing record testing volume and date of the Form 8-K filing. |
| 2026-11-17 | Date the Form 8-K was signed. |
Recommendation
holdThe filing shows positive operational momentum with record test volumes, indicating growing adoption of CyPath Lung. However, the company faces significant risks related to reimbursement, commercialization, and product development, as highlighted in its forward-looking statements. While promising, these factors warrant a cautious 'hold' recommendation until further clarity on revenue generation and profitability is achieved.
Keywords
CyPath Lung, lung cancer test, noninvasive test, flow cytometry, AI, sputum analysis, biotechnology, early detection
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.